<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00266279</url>
  </required_header>
  <id_info>
    <org_study_id>153.05</org_study_id>
    <nct_id>NCT00266279</nct_id>
  </id_info>
  <brief_title>Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies</brief_title>
  <official_title>Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>James Graham Brown Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II study will test the response rate of combined oxaliplatin and capecitabine&#xD;
      treatment when administered at a given dose and schedule, in patients with Head and Neck&#xD;
      cancer for which there is no curative treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The optimal dose and schedule for the combined treatment with oxaliplatin and capecitabine&#xD;
      have not been defined. The aim of this Phase II study is to determine the response rate of&#xD;
      combined oxaliplatin and capecitabine treatment at a given dose and schedule in patients with&#xD;
      Head and Neck cancer for which there is no curative treatment.&#xD;
&#xD;
      The study also aims to determine the qualitative and quantitative toxicity and reversibility&#xD;
      of toxicity of the above combination and to evaluate any changes in performance status,&#xD;
      quality of life, overall survival and progression-free survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Every two 28 day treatment cycles until subject no longer on treatment due to disease progression</time_frame>
    <description>Among the 15 patients treated, 2 (13%) achieved partial response (PR), and 5 (33%) achieved stable disease (SD), for a Overall Response Rate (ORR) of 46% measured by RECIST criteria.&#xD;
Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.&#xD;
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.&#xD;
Overall Response Rate (ORR)=PR+CR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Qualitative and Quantitative Toxicity</measure>
    <time_frame>At study enrollment, Every two 28 day treatment cycles, and at end of treatment due to disease progression</time_frame>
    <description>Number of patients that developed common side effect of diarrhea.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Head or Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment with Study Drugs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, Capecitabine</intervention_name>
    <description>Agent, DOSE AND SCHEDULE (28-days cycle):&#xD;
Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21</description>
    <arm_group_label>Treatment with Study Drugs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed squamous cell cancer of&#xD;
             Head and Neck&#xD;
&#xD;
          -  Patients must have metastatic or locally recurrent disease&#xD;
&#xD;
          -  Patients must have disease not curable by surgery as estimated by one of the protocol&#xD;
             investigators, and should not be eligible for reradiation protocol or have failed&#xD;
             reradiation protocol.&#xD;
&#xD;
          -  Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;20&#xD;
             mm with conventional techniques or as &gt;10 mm with spiral CT scan&#xD;
&#xD;
          -  Age &gt;18 years of age&#xD;
&#xD;
          -  Life expectancy of greater than 12 weeks&#xD;
&#xD;
          -  ECOG performance status 0, 1 or 2 (Karnofsky &gt;50%; see Appendix B)&#xD;
&#xD;
          -  Patients must have adequate bone marrow function as defined below:&#xD;
&#xD;
               -  absolute neutrophil count &gt; 1,500&#xD;
&#xD;
               -  platelets &gt; 100,000&#xD;
&#xD;
               -  hemoglobin &gt; 8 g/dl&#xD;
&#xD;
          -  Patients must have adequate renal function as defined by a creatinine clearance &gt;30&#xD;
             mL/min (measured or estimated by the Cockroft and Gault equation)&#xD;
&#xD;
               -  Cockroft and Gault equation:&#xD;
&#xD;
               -  Creatinine clearance for males =(140-age[yrs])(body wt[kg])/72(serum&#xD;
                  creatinine[mg/dL])&#xD;
&#xD;
               -  Creatinine clearance for females = 0.85 x male value&#xD;
&#xD;
          -  Patients must have adequate liver function as defined below:&#xD;
&#xD;
               -  total bilirubin 1.5x upper limit of normal&#xD;
&#xD;
               -  albumin &gt; 2.5 g/dl&#xD;
&#xD;
               -  AST(SGOT) and ALT(SGPT) and Alkaline Phosphatase must be &lt; 5 times upper limit of&#xD;
                  normal&#xD;
&#xD;
          -  Patients could have received 1 or 2 previous chemotherapy regimens prior to entering&#xD;
             the study. Patients must have recovered from acute toxicities from chemotherapy or&#xD;
             radiotherapy administered prior to entering this study. Alopecia may not be resolved&#xD;
             and peripheral neuropathy (grade 1) may be present.&#xD;
&#xD;
          -  Patients with reproductive potential must use an adequate contraceptive method (e.g.,&#xD;
             abstinence, intrauterine device, oral contraceptives, barrier device with spermicide&#xD;
             or surgical sterilization) during treatment and for three months after completing&#xD;
             treatment.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior unanticipated severe reaction to fluoropyrimidine therapy or known&#xD;
             hypersensitivity to 5-fluorouracil or oxaliplatin&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 4 weeks prior to first&#xD;
             treatment in this study or those who have not recovered from adverse events due to&#xD;
             agents administered more than 4 weeks earlier&#xD;
&#xD;
          -  Patients receiving any other investigational agent(s)&#xD;
&#xD;
          -  Patients with symptomatic brain metastases or actively receiving any therapy for brain&#xD;
             metastasis (because of their poor prognosis and because they often develop progressive&#xD;
             neurologic dysfunction that would confound the evaluation of neurologic and other&#xD;
             adverse events)&#xD;
&#xD;
          -  Active second malignancy in the last 5 years except for non-melanoma skin cancer or&#xD;
             carcinoma-in-situ&#xD;
&#xD;
          -  Clinically significant cardiac disease (e.g. congestive heart failure, New York Heart&#xD;
             Association Class II or greater, symptomatic coronary artery disease and cardiac&#xD;
             arrhythmias) or myocardial infarction within the last 12 months.&#xD;
&#xD;
          -  If patient is unable to swallow, xeloda may be crushed per hospital policy/procedure.&#xD;
             See attached Appendix G.&#xD;
&#xD;
          -  Patients who have had an organ allograft.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known Hepatitis B , Hepatitis C, HIV&#xD;
&#xD;
        Inclusion of Minorities:&#xD;
&#xD;
        Members of all ethnic groups are eligible for this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damian Laber, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville, James Graham Brown Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville, James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://browncancercenter.org</url>
    <description>James Graham Brown Cancer Center website</description>
  </link>
  <results_reference>
    <citation>Rabinowits G, Bhupalam L, Miller DM, Kloecker GH, Laber DA. Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck. Am J Med Sci. 2010 Feb;339(2):148-51. doi: 10.1097/MAJ.0b013e3181c4bd91.</citation>
    <PMID>20087165</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 15, 2005</study_first_submitted>
  <study_first_submitted_qc>December 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2005</study_first_posted>
  <results_first_submitted>May 3, 2013</results_first_submitted>
  <results_first_submitted_qc>October 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2014</results_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment With Study Drugs</title>
          <description>Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.&#xD;
Oxaliplatin, Capecitabine : Agent, DOSE AND SCHEDULE (28-days cycle):&#xD;
Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment With Study Drugs</title>
          <description>Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.&#xD;
Oxaliplatin, Capecitabine : Agent, DOSE AND SCHEDULE (28-days cycle):&#xD;
Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Among the 15 patients treated, 2 (13%) achieved partial response (PR), and 5 (33%) achieved stable disease (SD), for a Overall Response Rate (ORR) of 46% measured by RECIST criteria.&#xD;
Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.&#xD;
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.&#xD;
Overall Response Rate (ORR)=PR+CR.</description>
        <time_frame>Every two 28 day treatment cycles until subject no longer on treatment due to disease progression</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Study Drugs</title>
            <description>Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.&#xD;
Oxaliplatin, Capecitabine : Agent, DOSE AND SCHEDULE (28-days cycle):&#xD;
Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Among the 15 patients treated, 2 (13%) achieved partial response (PR), and 5 (33%) achieved stable disease (SD), for a Overall Response Rate (ORR) of 46% measured by RECIST criteria.&#xD;
Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.&#xD;
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.&#xD;
Overall Response Rate (ORR)=PR+CR.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Qualitative and Quantitative Toxicity</title>
        <description>Number of patients that developed common side effect of diarrhea.</description>
        <time_frame>At study enrollment, Every two 28 day treatment cycles, and at end of treatment due to disease progression</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Study Drugs</title>
            <description>Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.&#xD;
Oxaliplatin, Capecitabine: Agent, DOSE AND SCHEDULE (28-days cycle):&#xD;
Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21</description>
          </group>
        </group_list>
        <measure>
          <title>Qualitative and Quantitative Toxicity</title>
          <description>Number of patients that developed common side effect of diarrhea.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment With Study Drugs</title>
          <description>Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.&#xD;
Oxaliplatin, Capecitabine : Agent, DOSE AND SCHEDULE (28-days cycle):&#xD;
Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Bleeding</sub_title>
                <description>1 Subject experienced gastrointestinal bleeding.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>1 subjects was hospitalized for dehydration.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Two patients were hospitalized because of pneumonia.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Results data not available, PI not longer at institution</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>University of Louisville, James Graham Brown Cancer Center Clinical Trials</name_or_title>
      <organization>University of Louisville, James Graham Brown Cancer Center</organization>
      <phone>502-562-3429</phone>
      <email>bcccto@louisville.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

